ArticleJMA journal2025
Utilizing %Carbohydrate-deficient Transferrin as a Biomarker to Complement Interviews in Stratifying Alcohol Consumption in Patients with Alcohol Dependence: Aiming for Application to Fatty Liver Disease.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alcohol dependence is linked to various issues, including not only alcohol-associated/related liver disease (ALD) but also social isolation, making the assessment of alcohol consumption crucial for patient management. Meanwhile, a multisociety consensus group has introduced a new classification for steatotic liver disease (SLD), including ALD, based on alcohol consumption. The evaluation of alcohol intake uses tools such as the Alcohol Use Disorders Identification Test and Lifetime Drinking History; however, these tools may lack accuracy in clinical settings. Carbohydrate-deficient transferrin (%CDT) is a quantitative and objective biomarker for alcohol consumption. Therefore, we aimed to determine %CDT values that stratify alcohol consumption. Methods: This cross-sectional analysis included 285 serum samples from patients receiving inpatient or outpatient treatment at two specialized alcohol dependency medical centers. Participants were alcohol-dependent patients who underwent detailed interviews regarding alcohol consumption, biochemical blood tests, and %CDT testing. Results: Among the 285 samples, 32.6%, 19.6%, and 47.7% corresponded to alcohol consumption levels of ≤30 g/day for men/≤20 g/day for women, 30-60 g/day for men/20-50 g/day for women, and ≥60 g/day for men/≥50 g/day for women, respectively. %CDT values increased with increasing alcohol consumption (p < 0.05-0.0001). The cutoff values reflecting alcohol consumption of 30 g/day for men/20 g/day for women and 60g/day for men/50g/day for women were 1.67% and 2.48%, respectively. Gamma-glutamyl transferase (GGT) and GGT-CDT were able to distinguish between alcohol consumption above and below 60 g/day for men and 50 g/day for women (p < 0.0001). However, they had difficulty distinguishing between alcohol consumption above and below 30 g/day for men and 20 g/day for women. Conclusions: %CDT, in conjunction with detailed interviews, can be used to detect alcohol consumption, particularly to distinguish whether it exceeds 30 g/day in men and 20 g/day in women. Applying this to the clinical management of patients with alcohol dependence accompanied by ALD or SLD may contribute to improving the quality of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.